[A22-115] Ravulizumab (generalized myasthenia gravis) – Benefit assessment according to § 35a SGB V
Last updated 14.04.2023
Project no.:
A22-115
Commission:
Commission awarded on 21.10.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Immune system and infections
Adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Adults who are still eligible for standard treatment: added benefit not proven
- Adults with refractory disease: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-01.
| Project no. | Title | Status |
|---|---|---|
| A21-125 | Ravulizumab (paroxysmal nocturnal haemoglobinuria) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-68 | Ravulizumab (atypical haemolytic uraemic syndrome) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A23-50 | Ravulizumab (neuromyelitis optica spectrum disorder [NMOSD]) – Benefit assessment according to §35a Social Code Book V | Commission completed |